JP2006515004A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006515004A5 JP2006515004A5 JP2005518422A JP2005518422A JP2006515004A5 JP 2006515004 A5 JP2006515004 A5 JP 2006515004A5 JP 2005518422 A JP2005518422 A JP 2005518422A JP 2005518422 A JP2005518422 A JP 2005518422A JP 2006515004 A5 JP2006515004 A5 JP 2006515004A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- formula
- pharmaceutically acceptable
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 150000002825 nitriles Chemical class 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- XHSXSBMPWKBHJC-UHFFFAOYSA-N 3-(1h-indol-3-yl)-4-[6-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)pyridin-2-yl]pyrrole-2,5-dione Chemical compound C1CN(C)CCN1C1=CC=C(C(F)(F)F)C(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=N1 XHSXSBMPWKBHJC-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 238000003556 assay Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 102000015766 Protein Kinase C beta Human genes 0.000 description 1
- 108010024526 Protein Kinase C beta Proteins 0.000 description 1
- 102000014458 Protein Kinase C-epsilon Human genes 0.000 description 1
- 108010078137 Protein Kinase C-epsilon Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- -1 hydrochloric acid Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0303319.8A GB0303319D0 (en) | 2003-02-13 | 2003-02-13 | Organic compounds |
| PCT/EP2004/001323 WO2004072062A2 (en) | 2003-02-13 | 2004-02-12 | Indolylmaleimide derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009165725A Division JP2009280592A (ja) | 2003-02-13 | 2009-07-14 | インドリルマレイミド誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006515004A JP2006515004A (ja) | 2006-05-18 |
| JP2006515004A5 true JP2006515004A5 (enExample) | 2009-09-03 |
Family
ID=9952961
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005518422A Ceased JP2006515004A (ja) | 2003-02-13 | 2004-02-12 | インドリルマレイミド誘導体 |
| JP2009165725A Pending JP2009280592A (ja) | 2003-02-13 | 2009-07-14 | インドリルマレイミド誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009165725A Pending JP2009280592A (ja) | 2003-02-13 | 2009-07-14 | インドリルマレイミド誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7820672B2 (enExample) |
| EP (2) | EP2075249B1 (enExample) |
| JP (2) | JP2006515004A (enExample) |
| CN (1) | CN100439359C (enExample) |
| AT (2) | ATE463491T1 (enExample) |
| BR (1) | BRPI0407512A (enExample) |
| CA (1) | CA2513613A1 (enExample) |
| DE (1) | DE602004026415D1 (enExample) |
| ES (2) | ES2343115T3 (enExample) |
| GB (1) | GB0303319D0 (enExample) |
| PT (1) | PT1597250E (enExample) |
| WO (1) | WO2004072062A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602006019732D1 (de) | 2005-07-11 | 2011-03-03 | Novartis Ag | Indolylmaleimidderivate |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| EP2094689B1 (en) * | 2006-12-19 | 2013-04-03 | Novartis AG | Indolylmaleimide derivatives as kinase inhibitors |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CN101671329B (zh) * | 2009-06-17 | 2012-11-07 | 东华大学 | 3-氨基醇取代的吲哚马来酰亚胺化合物、其制备和应用 |
| CA2892927A1 (en) * | 2012-12-10 | 2014-06-19 | Centogene Ag | Use of maleimide derivatives for preventing and treating leukemia |
| CN104693198B (zh) * | 2014-12-13 | 2017-03-08 | 浙江工业大学 | 3‑(1,2,4‑三氮唑并[4,3‑a]吡啶‑3‑基)‑4‑(1H‑吲哚‑3‑基)马来酰亚胺类衍生物及其制备方法和应用 |
| SG11201708804WA (en) | 2015-05-07 | 2017-11-29 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| AU2016364889B2 (en) | 2015-12-02 | 2024-01-04 | Agenus Inc. | Antibodies and methods of use thereof |
| EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE |
| WO2018132636A1 (en) * | 2017-01-12 | 2018-07-19 | The Research Foundation For The State University Of New York | [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method |
| CN110551103B (zh) * | 2018-05-30 | 2022-08-23 | 北京大学深圳研究生院 | 一种jak3选择性抑制剂 |
| AU2020218366A1 (en) | 2019-02-08 | 2021-09-16 | Frequency Therapeutics, Inc. | Valproic acid compounds and Wnt agonists for treating ear disorders |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0629947B2 (ja) | 1986-07-16 | 1994-04-20 | 正浩 入江 | 光学記録材料 |
| IL89167A (en) | 1988-02-10 | 1994-02-27 | Hoffmann La Roche | Substituted pyrroles, their manufacture and pharmaceutical compositions containing them |
| DE4005970A1 (de) | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
| GB9123396D0 (en) | 1991-11-04 | 1991-12-18 | Hoffmann La Roche | A process for the manufacture of substituted maleimides |
| AU3761393A (en) | 1992-03-20 | 1993-10-21 | Wellcome Foundation Limited, The | Indole derivatives with antiviral activity |
| JPH06161024A (ja) | 1992-11-26 | 1994-06-07 | Sanyo Electric Co Ltd | 光学記録材料 |
| US5405864A (en) | 1993-10-15 | 1995-04-11 | Syntex (U.S.A.) Inc. | Chemotherapeutic maleimides |
| US5559228A (en) | 1995-03-30 | 1996-09-24 | Eli Lilly And Company | Synthesis of bisindolylmaleimides |
| JPH0961647A (ja) | 1995-08-25 | 1997-03-07 | Nippon Telegr & Teleph Corp <Ntt> | 光素子用有機材料 |
| FR2772266B1 (fr) | 1997-12-12 | 2000-02-04 | Oreal | Utilisation d'agent de coloration photochrome dans une composition cosmetique, et composition cosmetique le comprenant |
| EP1119548B1 (en) | 1998-10-08 | 2004-12-08 | SmithKline Beecham plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione as glycogen synthase kinase-3 inhibitor (gsk-3) |
| GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| US6359150B1 (en) | 1999-08-31 | 2002-03-19 | Kyocera Corporation | Photochromic compound and optical function device using the same |
| AU1189201A (en) | 1999-10-22 | 2001-05-08 | Eli Lilly And Company | Therapeutic compositions including protein kinase c inhibitors |
| US6281356B1 (en) | 1999-12-22 | 2001-08-28 | Hoffmann-La Roche Inc. | Substituted pyrroles |
| MXPA02011079A (es) | 2000-05-11 | 2004-08-19 | Consejo Superior Investigacion | Inhibidores heterociclicos de quinasa de sintasa de glucogeno gsk3. |
| ATE284885T1 (de) | 2000-07-27 | 2005-01-15 | Hoffmann La Roche | 3-indolyl-4-phenyl-1h-pyrrol-2,5-dion derivate als glycogen synthase kinase 3beta inhibitoren |
| KR100748386B1 (ko) | 2000-11-07 | 2007-08-10 | 노파르티스 아게 | 단백질 키나제 ｃ 억제제로서의 인돌릴말레이미드 유도체 |
| JP2002285146A (ja) | 2001-03-27 | 2002-10-03 | Masahiro Irie | フォトクロミック組成物及び線量計 |
| DE60209471D1 (de) | 2001-03-29 | 2006-04-27 | Topo Target As Copenhagen Koeb | Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii |
| BE1014306A6 (fr) | 2001-07-19 | 2003-08-05 | Project 21C | Dispositif de stationnement d'un cycle avec antivol. |
| WO2003076398A2 (en) * | 2002-03-08 | 2003-09-18 | Eli Lilly And Company | Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors |
| PE20040079A1 (es) * | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
-
2003
- 2003-02-13 GB GBGB0303319.8A patent/GB0303319D0/en not_active Ceased
-
2004
- 2004-02-12 EP EP09004073A patent/EP2075249B1/en not_active Expired - Lifetime
- 2004-02-12 CN CNB2004800029076A patent/CN100439359C/zh not_active Expired - Fee Related
- 2004-02-12 AT AT04710393T patent/ATE463491T1/de active
- 2004-02-12 DE DE602004026415T patent/DE602004026415D1/de not_active Expired - Lifetime
- 2004-02-12 ES ES04710393T patent/ES2343115T3/es not_active Expired - Lifetime
- 2004-02-12 AT AT09004073T patent/ATE551335T1/de active
- 2004-02-12 BR BRPI0407512-9A patent/BRPI0407512A/pt not_active IP Right Cessation
- 2004-02-12 PT PT04710393T patent/PT1597250E/pt unknown
- 2004-02-12 EP EP04710393A patent/EP1597250B8/en not_active Expired - Lifetime
- 2004-02-12 WO PCT/EP2004/001323 patent/WO2004072062A2/en not_active Ceased
- 2004-02-12 US US10/542,175 patent/US7820672B2/en not_active Expired - Fee Related
- 2004-02-12 CA CA002513613A patent/CA2513613A1/en not_active Abandoned
- 2004-02-12 JP JP2005518422A patent/JP2006515004A/ja not_active Ceased
- 2004-02-12 ES ES09004073T patent/ES2385071T3/es not_active Expired - Lifetime
-
2009
- 2009-07-14 JP JP2009165725A patent/JP2009280592A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006515004A5 (enExample) | ||
| EP2429986B1 (en) | Haloalkyl heteroaryl benzamide compounds | |
| CN100351251C (zh) | 吲哚基马来酰亚胺衍生物 | |
| EP2877457B1 (en) | Cystathionine-gamma-lyase (cse) inhibitors | |
| JP4792025B2 (ja) | ５−ヒドロキシインドール−３−カルボン酸エステル類誘導体およびその用途 | |
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| JP2006523216A5 (enExample) | ||
| WO2007139150A1 (ja) | ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤 | |
| JP2005506368A (ja) | 肥満の処置におけるまたは食物摂取の減少のためのインドールおよびインドリン誘導体の使用 | |
| CN115667209A (zh) | 用于治疗sars的化合物 | |
| US12064410B2 (en) | Compositions and methods for stimulating ventilatory and/or respiratory | |
| WO2019046287A1 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | |
| US20200323828A1 (en) | Methods of treating behavior alterations | |
| CN100361975C (zh) | 5－羟基－3－羧酸酯吲哚类衍生物及其制备方法 | |
| US6455567B1 (en) | Method of treatment | |
| HUP0002966A2 (hu) | Alfa-2-adrenoreceptor agonistákként alkalmazható [(2-imidazolidinilidén)-amino]-benzoxazol-származékok és az ezeket tartalmazó gyógyszerkészítmények | |
| CN101663035B (zh) | 4-环丙基甲氧基-n-(3，5-二氯代-1-氧化-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺在制备用于治疗与帕金森症有关的运动障碍的药物中的用途 | |
| JP2007507472A5 (enExample) | ||
| US20070004777A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
| JP7535797B2 (ja) | 化合物バフィデムスタット（ｖａｆｉｄｅｍｓｔａｔ）などｋｄｍ１ａ阻害剤を使用した注意欠陥多動性障害の処置方法 | |
| CN100584828C (zh) | 新的5-羟基吲哚-3-羧酸酯类衍生物 | |
| JP2019535680A (ja) | キナーゼを阻害する組成物及び方法 | |
| US10543187B2 (en) | Compositions and methods for stimulating ventilatory and/or respiratory drive | |
| CN101663036B (zh) | 4-环丙基甲氧基-n-(3,5-二氯代-1-氧代-4-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺用于治疗颅脑创伤的用途 | |
| JP2004002272A (ja) | ２型糖尿病治療剤 |